Advertisement
BIO or DHR or MTD
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher Corporation (DHR) vs. Mettler-Toledo International (MTD) Stock Comparison
Key Takeaways
- Bio-Rad Laboratories (BIO) delivered flat revenue growth in fiscal 2025, with GAAP (Generally Accepted Accounting Principles) earnings heavily distorted by its Sartorius AG equity investment, while non-GAAP operating margins contracted amid constrained academic research funding.
- Danaher Corporation (DHR) returned to modest revenue growth of 2.9% in 2025, supported by its high-margin recurring revenue base that represents over 83% of total sales, though EPS (earnings per share) has been on a multi-year decline trajectory.
- Mettler-Toledo International (MTD) posted the strongest revenue acceleration among the three, with 4% full-year 2025 top-line growth and a notable second-half rebound driven by industrial demand and the Spinnaker sales program.
- All three companies operate in the life sciences and precision tools ecosystem but face divergent headwinds: BIO struggles with academic funding pressures, DHR navigates post-pandemic normalization, and MTD contends with tariff-related cost headwinds.
- MTD's aggressive share repurchase authorization of $2.75 billion and projected 8–9% Adjusted EPS growth in 2026 signal management confidence, while BIO's margin compression and DHR's EPS erosion remain key investor concerns.
- From a relative performance standpoint, MTD's combination of accelerating revenue, strong free cash flow conversion, and shareholder returns gives it a distinguishable edge in the current market environment.
Introduction
Investors evaluating the life sciences and precision instrumentation sector often encounter three prominent but fundamentally distinct names: BIO, DHR, and MTD. Bio-Rad Laboratories, Danaher Corporation, and Mettler-Toledo International each occupy different niches — clinical diagnostics and life science research, diversified life sciences and biotechnology tools, and precision weighing and analytical instruments, respectively. This stock comparison examines how these three companies have navigated recent market conditions, where their growth drivers diverge, and how their relative performance stacks up. Whether you are a long-term growth investor seeking scientific innovation exposure or a tactical trader evaluating sector momentum, understanding the contrasts among these three names is essential for informed decision-making.
BIO Overview and Recent Performance
BIO, Bio-Rad Laboratories, is a global leader in life science research and clinical diagnostics products, headquartered in Hercules, California. The company operates through two primary segments: Life Science and Clinical Diagnostics. In recent months, Bio-Rad's stock has faced considerable pressure, reflecting a challenging operating environment. Full-year 2025 revenue came in at $2.58 billion, representing a marginal 0.7% increase year-over-year, with currency-neutral sales essentially flat. While the Clinical Diagnostics segment showed resilience — growing 8.4% in Q4 2025 on a reported basis — the Life Science segment contracted amid constrained academic research and biotech funding. Non-GAAP gross margins declined from 55.0% in 2024 to 53.3% in 2025, and non-GAAP net income slipped to $270.5 million from $291.1 million. A major complicating factor for BIO investors is the company's large equity stake in Sartorius AG, which introduces substantial GAAP earnings volatility unrelated to underlying operations. On a positive note, Bio-Rad's acquisition of Stilla Technologies has expanded its Droplet Digital PCR (polymerase chain reaction) portfolio, and the company generated $375 million in free cash flow during 2025. Looking ahead, management guided for currency-neutral revenue growth of just 0.5% to 1.5% in 2026, with non-GAAP operating margins projected at 12.0% to 12.5%.
DHR Overview and Recent Performance
DHR, Danaher Corporation, is a diversified global science and technology innovator headquartered in Washington, D.C. The company designs, manufactures, and markets professional, medical, industrial, and commercial products across biotechnology, life sciences, and diagnostics. In recent market activity, Danaher has demonstrated a recovery from its post-pandemic demand normalization. Full-year 2025 revenue reached $24.57 billion, an increase of 2.9% year-over-year, breaking a multi-year streak of revenue declines. A defining characteristic of Danaher's business model is its high proportion of recurring revenue, which stood at 83.7% of total sales in Q2 2025, lending stability to its financial profile. The biotechnology segment has been a particularly bright spot, with 8% year-over-year growth in mid-2025. However, diluted EPS has been trending in the wrong direction, declining from $9.64 in 2022 to $5.05 in 2025, partly reflecting the impact of the Veralto spin-off and ongoing portfolio reshaping. The company has been actively reorganizing its life sciences businesses to address changing customer needs. Danaher's ROE (return on equity) stood at approximately 7.0% at year-end 2025, and its ROI (return on investment) was 6.82%, figures that reflect the capital-intensive nature of its operations and the lingering effects of acquisition-related amortization. The stock has experienced notable volatility in recent months, with a 52-week range spanning from approximately $171 to $258.
MTD Overview and Recent Performance
MTD, Mettler-Toledo International, is the world's largest manufacturer and marketer of precision instruments — primarily weighing equipment — for laboratory, industrial, and food retailing applications. Headquartered in Columbus, Ohio, the company has demonstrated the strongest momentum among the three in recent quarters. Full-year 2025 revenue grew 4% to $4.03 billion, with local currency sales up 3%. Adjusted EPS rose to $42.73, a 4% increase over 2024. The second half of 2025 was particularly robust: Q3 reported sales jumped 8% with 6% local currency growth, driven by strong industrial demand and the company's Spinnaker sales and marketing program. Q4 delivered an 8% reported sales increase and 5% local currency growth. The Americas and Europe were standout regions, with Americas local currency sales up 5% for the full year. Mettler-Toledo's Board of Directors authorized an additional $2.75 billion share repurchase program in Q3 2025, bringing total authorization to $3.85 billion — a significant signal of management confidence. For 2026, management has guided for approximately 4% local currency sales growth and Adjusted EPS of $46.05 to $46.70, representing 8% to 9% growth. Gross margins have remained healthy at around 59%, and the company's adjusted operating margin of roughly 30% is the highest among the three companies compared here. Tariff-related costs remain a headwind, but management has actively pursued mitigation strategies.
Trending AI Robots
For traders seeking a data-driven edge in navigating stocks like BIO, DHR, and MTD, Tickeron's Trending AI Robots page offers a curated gateway into algorithmic trading. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of different tickers across diverse strategies and timeframes. However, only the most consistently effective and market-adaptive bots earn a place in the Trending section — a real-time selection of top performers aligned with current market conditions. These bots vary widely in trading style, ranging from short-term swing trading to longer-duration trend-following approaches, with documented performance statistics including annualized returns, trade accuracy rates, and drawdown metrics that can reach into double-digit gains per trade. Each bot operates with a distinct set of tickers, making it possible to find strategies tailored to specific stocks or sectors. Exploring the Trending AI Robots page can help investors discover which algorithmic approaches are currently favored by quantitative signals.
Head-to-Head Comparison
When comparing BIO, DHR, and MTD, several structural differences stand out. In terms of scale, Danaher is the dominant player with a market capitalization of roughly $144 billion — more than five times Mettler-Toledo's $26.5 billion and nearly 18 times Bio-Rad's $8.2 billion. DHR's size and diversification, particularly its 83.7% recurring revenue base, provide a stability cushion that the other two lack. However, DHR's EPS has eroded for three consecutive years, raising questions about the pace of organic earnings recovery.
Mettler-Toledo occupies the most attractive position on operational momentum. Its 2025 revenue growth of 4% and projected 8–9% Adjusted EPS expansion in 2026 outpace both peers. The company's aggressive share buyback program — $2.75 billion in fresh authorization — should provide a tailwind to per-share metrics. MTD also enjoys the highest operating margins of the group, with adjusted operating margins consistently near or above 30%.
Bio-Rad presents the most idiosyncratic risk profile. Its large Sartorius AG equity stake (valued at $5.67 billion as of December 31, 2025) creates dramatic GAAP earnings swings — from a $1.84 billion net loss in 2024 to a $760 million net profit in 2025 — that have little to do with the underlying business. Strip that away, and the picture is one of flat revenue, declining margins, and limited near-term growth visibility. The Stilla Technologies acquisition offers a long-term growth pathway in digital PCR, but near-term catalysts remain limited.
Sector exposure also differs meaningfully. BIO is heavily tied to academic and biotech research funding cycles, which have been under pressure. DHR's broad portfolio spans bioprocessing, diagnostics, and water quality, offering multiple growth vectors but also exposure to China-related headwinds. MTD's industrial and laboratory end-markets benefit from secular trends in automation and quality control, though tariff exposure introduces a near-term overhang.
Tickeron AI Verdict
Based on observable factors including trend consistency, growth trajectory, margin stability, and capital allocation discipline, Tickeron's AI would likely favor MTD in the current market environment. Mettler-Toledo's combination of accelerating revenue growth, industry-leading operating margins, a substantial share repurchase program, and a clearly articulated 8–9% EPS growth outlook for 2026 provides a more compelling quantitative profile than the flatter trajectories seen at BIO and the EPS erosion challenge at DHR. Danaher's scale and recurring revenue model offer defensive characteristics that AI-driven trend analysis would still view favorably relative to Bio-Rad's volatility-laden and margin-compressed setup. The AI would likely rank MTD first on momentum and quality metrics, with DHR as a stable but slower-growth alternative, and BIO trailing on relative strength due to persistent operational headwinds. As always, AI-driven assessments reflect probabilistic pattern analysis rather than certainty, and market conditions can shift the relative attractiveness of each name.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and MTD’s FA Score reflects 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 6 bullish TA indicator(s), and MTD’s TA Score reflects 5 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 3 bearish.
- DHR’s TA Score: 6 bullish, 4 bearish.
- MTD’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +2.79% price change this week, while DHR (@Medical Specialties) price change was +2.40% , and MTD (@Medical Specialties) price fluctuated +1.07% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.41%. For the same industry, the average monthly price growth was -1.86%, and the average quarterly price growth was -18.22%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.78%. For the same industry, the average monthly price growth was +12.92%, and the average quarterly price growth was +4.71%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
DHR is expected to report earnings on Jul 21, 2026.
MTD is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.41% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | DHR | MTD | |
| Capitalization | 8.17B | 144B | 26.5B |
| EBITDA | 440M | 7.08B | 1.25B |
| Gain YTD | 0.452 | -10.585 | -6.037 |
| P/E Ratio | 50.64 | 39.50 | 30.77 |
| Revenue | 2.59B | 24.8B | 4.09B |
| Total Cash | 1.57B | N/A | 60.6M |
| Total Debt | 1.38B | 18.5B | 2.23B |
BIO | DHR | MTD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 38 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 10 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 80 | 2 | |
PRICE GROWTH RATING 1..100 | 49 | 48 | 49 | |
P/E GROWTH RATING 1..100 | 10 | 44 | 47 | |
SEASONALITY SCORE 1..100 | 90 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for BIO (83) and is significantly better than the same rating for MTD (99). This means that DHR's stock grew significantly faster than BIO’s and significantly faster than MTD’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100) and is in the same range as MTD (100). This means that DHR's stock grew similarly to BIO’s and similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for DHR (80) and is significantly better than the same rating for BIO (90). This means that MTD's stock grew significantly faster than DHR’s and significantly faster than BIO’s over the last 12 months.
DHR's Price Growth Rating (48) in the Medical Specialties industry is in the same range as MTD (49) and is in the same range as BIO (49). This means that DHR's stock grew similarly to MTD’s and similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for DHR (44) and is somewhat better than the same rating for MTD (47). This means that BIO's stock grew somewhat faster than DHR’s and somewhat faster than MTD’s over the last 12 months.
| BIO | DHR | MTD | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 53% | 3 days ago 76% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 68% | 3 days ago 69% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 51% | 3 days ago 56% |
| MACD ODDS (%) | 3 days ago 63% | 3 days ago 47% | N/A |
| TrendWeek ODDS (%) | 3 days ago 66% | 3 days ago 55% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 53% | 3 days ago 58% |
| Advances ODDS (%) | 3 days ago 66% | 4 days ago 54% | 4 days ago 60% |
| Declines ODDS (%) | 12 days ago 68% | 20 days ago 61% | N/A |
| BollingerBands ODDS (%) | 3 days ago 70% | 3 days ago 67% | 3 days ago 69% |
| Aroon ODDS (%) | 3 days ago 75% | 3 days ago 55% | 3 days ago 53% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.58% | ||
| TMO - DHR | 77% Closely correlated | -1.97% | ||
| A - DHR | 73% Closely correlated | -3.41% | ||
| RGEN - DHR | 68% Closely correlated | -0.88% | ||
| RVTY - DHR | 64% Loosely correlated | -1.33% | ||
| BIO - DHR | 64% Loosely correlated | +1.12% | ||
More | ||||
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -1.88% | ||
| A - MTD | 71% Closely correlated | -3.41% | ||
| TMO - MTD | 68% Closely correlated | -1.97% | ||
| BRKR - MTD | 67% Closely correlated | -1.72% | ||
| DHR - MTD | 64% Loosely correlated | -0.58% | ||
| AZTA - MTD | 61% Loosely correlated | -1.83% | ||
More | ||||